VOYA Investment Management’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.18M Buy
45,823
+22,151
+94% +$455K ﹤0.01% 1440
2026
Q1
$455K Sell
23,672
-133
-0.6% -$2.65K ﹤0.01% 1759
2025
Q4
$393K Hold
23,805
﹤0.01% 1857
2025
Q3
$346K Sell
23,805
-12,103
-34% -$174K ﹤0.01% 1927
2025
Q2
$502K Sell
35,908
-15,103
-30% -$213K ﹤0.01% 1896
2025
Q1
$693K Sell
51,011
-3,802
-7% -$72.8K ﹤0.01% 1721
2024
Q4
$1.12M Sell
54,813
-2,991
-5% -$76.6K ﹤0.01% 1539
2024
Q3
$1.68M Sell
57,804
-976
-2% -$24.2K ﹤0.01% 1397
2024
Q2
$1.36M Sell
58,780
-161,858
-73% -$3.11M ﹤0.01% 1465
2024
Q1
$4.53M Sell
220,638
-63,466
-22% -$1.19M ﹤0.01% 1049
2023
Q4
$6.1M Buy
284,104
+19,488
+7% +$386K 0.01% 922
2023
Q3
$5.46M Buy
264,616
+1,109
+0.4% +$28.1K 0.01% 934
2023
Q2
$7.78M Buy
263,507
+71,779
+37% +$2.02M 0.01% 820
2023
Q1
$4.42M Buy
191,728
+21,854
+13% +$601K ﹤0.01% 1035
2022
Q4
$4.72M Buy
169,874
+3,938
+2% +$117K 0.01% 995
2022
Q3
$5.09M Sell
165,936
-64,894
-28% -$2.11M 0.01% 943
2022
Q2
$6.79M Buy
230,830
+99,848
+76% +$2.62M 0.02% 616
2022
Q1
$4.21M Buy
130,982
+95,909
+273% +$3.3M 0.01% 887
2021
Q4
$1.56M Sell
35,073
-518
-1% -$24.5K ﹤0.01% 1280
2021
Q3
$1.8M Sell
35,591
-174
-0.5% -$9.81K ﹤0.01% 1227
2021
Q2
$2.81M Buy
35,765
+8,192
+30% +$507K 0.01% 1060
2021
Q1
$1.57M Buy
27,573
+223
+0.8% +$14.9K ﹤0.01% 1302
2020
Q4
$2.29M Buy
27,350
+5,468
+25% +$331K ﹤0.01% 1079
2020
Q3
$784K Hold
21,882
﹤0.01% 1419
2020
Q2
$529K Sell
21,882
-3,203
-13% -$75.3K ﹤0.01% 1630
2020
Q1
$439K Buy
25,085
+1,788
+8% +$37.3K ﹤0.01% 1688
2019
Q4
$406K Buy
23,297
+3,867
+20% +$64.4K ﹤0.01% 2004
2019
Q3
$298K Hold
19,430
﹤0.01% 2043
2019
Q2
$403K Buy
19,430
+829
+4% +$18.6K ﹤0.01% 1917
2019
Q1
$432K Hold
18,601
﹤0.01% 1860
2018
Q4
$384K Buy
18,601
+1,803
+11% +$32.7K ﹤0.01% 1883
2018
Q3
$365K Buy
+16,798
New +$278K ﹤0.01% 2035

Other funds holding DNLI

VOYA Investment Management's DNLI Position: Q2 2026 in Review

VOYA Investment Management increased its Denali Therapeutics (DNLI) stake by 94% in Q2 2026, buying an estimated $455K and bringing the position to 45,823 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #1440.

VOYA Investment Management first reported a position in DNLI in Q3 2018 and has held it in 32 quarters since. The position peaked at $7.78M in Q2 2023. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • VOYA Investment Management held 45,823 shares of Denali Therapeutics worth $1.18M as of Q2 2026.
  • VOYA Investment Management bought 22,151 Denali Therapeutics shares in Q2 2026, an estimated $455K.
  • Denali Therapeutics made up ﹤0.01% of VOYA Investment Management's portfolio in Q2 2026, its #1440 holding.
  • VOYA Investment Management first reported a position in Denali Therapeutics in Q3 2018 and has held it in 32 quarters since.
  • VOYA Investment Management's Denali Therapeutics position peaked at $7.78M in Q2 2023.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.